Skip to Content

'
Kevin B. Kim

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Research Interests

Melanoma, Mucosal Melanoma, Targeted Therapy

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 430
Houston, TX 77030
Phone: 713-792-2921
Fax: 713-745-1046

Education & Training

Degree-Granting Education

1995 University of Illinois at Chicago, College of Medicine, Chicago, IL, MD, Medicine
1990 University of California at Berkeley, Berkeley, CA, BA, Biochemistry

Postgraduate Training

1998-2001 Fellowship, Medical Oncology/Hematology, University of Texas, M.D. Anderson Cancer Center, Houston, TX
1996-1998 Residency, Internal Medicine, Mayo Clinic, Rochester, MN

Board Certifications

11/2001 American Board of Medical Oncology

Selected Publications

Peer-Reviewed Original Research Articles
1. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P. A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma. Cancer Invest 27(7):756-63, 8/2009. e-Pub 5/2009. PMID: 19440934.
2. Kim KB, Hwu WJ, Papadopoulos NE, Bedikian AY, Camacho LH, Ng C, Hernandez IM, Frost AM, Jack MA, Hwu P. Phase I study of the combination of Docetaxel, Temozolomide and Cisplatin in patients with Metastatic Melanoma. Cancer Chemother Pharmacol 64(1):161-7, 2009 Jun, 6/2009. e-Pub 11/2008. PMID: 19002462.
3. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Roe AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 19(1):42-49, 2/2009. PMID: 19430405.
4. Bedikian AY, Papadopoulos NE, Kim KB, Vardeleon A, Smith T, Lu B, Deitcher SR. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Melanoma Res 18(6):400-4, 12/2008. PMID: 19011511.
5. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P. Complete Response of Stage IV Anal Mucosal Melanoma Expressing KIT Val560Asp to the Multikinase Inhibitor Sorafenib. Nat Clin Pract Oncol 5(12):737-40, 12/2008. e-Pub 10/2008. PMID: 18936790.
6. Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, Hwu P, Kim KB. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 30(12):1592-1598, 9/2008. PMID: 18798304.
7. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, NG CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II Trial of Imatinib Mesylate in patients with Metastatic Melanoma. Brit J Cancer 99(5):734-740, 9/2008. PMID: 18728664.
8. Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res 18(4):241-5, 8/2008. PMID: 18626307.
9. Bedikian AY, Johnson MM, Warneke CL, Paapdopoulos NE, Kim K, Hwu WJ, McIntyre S, Hwu P. Prognostic Factors that determine the Long-Term survival of patients with unresectable Metastatic Melanoma. Cancer Invest 26(6):624-633, 7/2008. PMID: 18584354.
10. Hemrajani RH, Kim KB, Amos WR, Mann DE. Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence. Melanoma Res. 17:257-259, 8/2007.
11. Kim KB, Faderl S, Hwang CS, Khuri FR. Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature. J Clin Pharm Ther 31:401-6, 8/2006. PMID: 16882113.
12. Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol 33:280-5, 4/2006. PMID: 16630177.
13. Kim KB, Bedikian AY, Camacho LH, Papadopoulos NE, McCullough C. A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 104:1687-92, 10/2005. PMID: 16130126.
14. Ballo MT, Zagars GK, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, Camacho LH, Hwu P, Ross MI. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 11:1079-84, 12/2004. PMID: 15576833.
15. Harting MS, Kim KB. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. Melanoma Res 14:517-20, 12/2004. PMID: 15577323.
16. Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer 101:596-603, 8/2004. PMID: 15274073.
17. Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 100:1478-83, 4/2004. PMID: 15042682.
18. Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA, Bedikian AY, Kim KB, Papadopoulos NE, Prieto VG, Ross MI. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 20:4555-8, 12/2002. PMID: 12454112.

Last updated: 9/1/2009